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Abstract 
The cervical cancer is affecting the lower parts of the uterus. Human papillomavirus is a main 
reason for developing cervical cancer. The incidence of cervical cancer has been declining in the 
European Union since the 1980s, with the exception of Eastern European countries that later 
joined the alliance. In order to prepare this paper, were used data from WHO. Mortality rates are 
characterized by slower declines in some Eastern European countries or remain consistently high 
as in Slovakia, Estonia and Bulgaria while Finland, Switzerland and Malta are characterized by 
lowest morbidity rates. It is currently the fourth most common malignant cancer in women in 
terms of morbidity and the seventh most common cancer in the general global population. 
According to data from 2018, from the Global Cancer Registry (Globocan 2018), cervical cancer 
contributes to 3.2% or 569 847 cases of all newly diagnosed cases of cancer globally, and is 
responsible for 3.15% of deaths in general of all types of cancer. Among the women diagnosed 
with cervical cancer between 2010 and 2014, the 5-year survival varies between the member 
states, from 54% in Latvia to 70% in Denmark. The average five-year survival in the European 
Union in the last decade has increased from 61% to 63%. Cervical cancer mortality among 
European Union members decreased from 6.0 in 2000 to 5.1 in 2015. These trends suggest the 
need for timely and properly developed prevention programs, implementation of organized 
screenings, early diagnosis and effective treatment for cervical cancer. 
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Introduction 
Cervical cancer is a cancer that affects the lower part of the uterus that connects it to the cervix. 
It can occur in the reproductive period, adolescence period and until menopause. Cervical cancer 
is caused by the sexually transmitted HPV virus, which is the most common viral infection of the 
reproductive tract. Almost every sexually active individual will be infected with HPV at some 
point in their lives, and some may be re-infected with the same or different type of virus. 
The symptoms of cervical cancer are non-specific and their intensity depends on the degree of 
progression of the disease. Vaginal discharge and bleeding from the birth canal are the most 
common reasons to visit a gynecologist, although they can be symptoms of cancer and are more 
common in inflammatory reactions of the vagina or some hormonal imbalances. Other 
nonspecific symptoms of cervical cancer include lower abdominal pain, sacral pain, or pain in 
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the acetabul of emoral joint of the pelvis. Symptoms such as sudden vaginal bleeding, 
leukorrhea, dyspareunia (painful intercourse) and dysuria may occur as the disease progresses, 
and symptoms such as hepatic pain, dyspnea may occur.
 
Important risk factors for the development of CIN and invasive cervical cancer are: early coitus 
(early onset of sexual intercourse), more sexual partners, male partner with multiple previous 
sexual partners, a large number of abortions, persistent infection with oncogenic papilloma–
viruses, Herpes Simplex infection Type 2, Chlamydia, HIV, - deficiency of provitamin A, 
vitamin C and carotenides, positive family history of cervical cancer. Genetic inheritance is 
responsible for 27% of the risk factors for developing cancer. Heredity can trigger many factors 
that contribute to the development of cervical cancer, including susceptibility to HPV infection, 
the body's ability to defend itself against infection, and the time it takes for the disease to 
develop.
 
Fifteen of the fourteen types of HPV that invade the genital tract have been shown to be 
oncogenic, ie types 16, 18, 45, 31, 33, 52, 58, 35, 59, 56, 39, 51, 73, 68 and 66 - sorted by 
frequency from most common to least common. In contrast, condyloma, which is a benign 
lesion, is associated with low-risk HPV infection at 6, 11, 42, and 44. 
Cervical cancer is classified according to the International Federation of Gynecologists and 
Obstetricians (FIGO). FIGO classification is based on tumor size, vaginal or parametric 
involvement, bladder / rectal spread, and distant metastases.  Recently, positron emission 
tomography (RET) has been shown to have the potential to accurately describe the extent of the 
disease, especially in lymph nodes that are not macroscopically enlarged and distant, with high 
sensitivity and specificity.  
In order to properly prevent and control cervical cancer, multidisciplinary engagement is 
necessary starting from educational programs, social mobilization, vaccination, screening, 
treatment and palliative care. [1-13] 
Material and methods 
For the purposes of the research, data were taken on patients diagnosed with cervical cancer from 
the World Health Organization – WHO. Additional data was provided by the International 
Agency for Research on Cancer through the second report on 'Cancer Screening in the European 
Union' with the participation of 60 experts in the field, from 22 member countries under the 
supervision of the European Commission. Approximately 67.5 million women from the member 
states of the union are within the selected age target group of 30-59 years, which is the minimum 
age range according to many European recommendations. All data taken for cervical cancer 
(incidence and mortality) in the Member States of the European Union, which are included in 
this paper, are based on online data collection. 
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Results and discussion 
Table 1. Cervical cancer prevalence in EU countries in 2012. 
 
 
Таble 1. 
Cervical cancer prevalence in EU countries in 2012. 
Number of cases and deaths according to E – ASR 
Incidence Моrtality 
Num. of cases       Х 
100 
E – ASR 
/100 000 
Num. of death cases 
Х 100 
E – ASR 
/100 000 
Аustria 3,6 7,0 1,8 2,8 
Belgium 6,4 10,2 2,2 2,7 
Bulgaria 12,5 28,5 4,4 8,8 
Cyprus 3,3 12,1 1,4 4,3 
Croatia 0,3 5,2 0,2 2,5 
Czech Republic 10,2 16,3 3,2 4,3 
Denmark 3,6 12,1 1,0 2,6 
Еstonia 1,9 23,3 0,8 8,1 
Finland 1,4 4,9 0,5 1,4 
France 28,6 8,0 11,7 2,6 
Germany 50,0 9,8 15,7 2,4 
Greece 4,2 6,2 2,1 2,5 
Hungary 11,8 20,5 4,6 6,9 
Ireland 3,6 15,1 1,0 4,3 
Italy 29,2 7,7 10,2 2,0 
Latvia 2,8 20,7 1,4 8,2 
Lithuania 6,2 31,6 2,2 9,8 
Luxembourg 0,2 7,1 0,1 3,7 
Маlta 0,1 4,6 0,0 1,1 
Netherlands 7,5 8,0 2,4 2,1 
Poland 35,1 15,3 18,6 7,4 
Portugal 7,2 10,8 3,9 4,9 
Romania 43,4 34,9 19,1 14,2 
R.Slovakia 6,1 19,4 2,3 6,9 
Slovenia 1,4 11,8 0,6 4,1 
Spain 25,1 9,1 8,5 2,7 
Sweden 4,5 8,6 1,9 2,6 
Total 310,2  130,6  
 
According to the data, in 2012 in the EU were reported over 316 000 cases of cervical cancer. Of 
these, most cases were reported in Germany – 50.000, Romania = 43.400, Poland – 35.000 and 
Italy – 29.000 cases. The lowest number of cases were reported in Malta - around 1,000 cases 
and Luxembourg - 2,000 cases. According to the number of deceased patients, the highest 
number is recorded in Romania - around 20,000 cases, Poland - 18,000 and Germany - 15,000 
cases. The lowest number of deaths is in Malta with less than 10 death cases and Luxembourg 
with less than 20 death cases. However these are not large countries and according to the 
population they have a mortality of 1.1/100 000 and 3.7/100 000, respectively. On average, the 
incidence of cervical cancer in the member states of the European Union for 2012 is 13.6/100 
000. The mortality rate for the same year is 4.6. The number of deaths is 131,000. 
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Table 2. Cervical cancer screening programs in European Union Member States in 2016 
 
Табела 2. Cervical cancer screening programs in the member states of the European Union in 2016 
 
Population estimates by screening test, program type and status 
implementation by member states 
 
 
Member 
States 
 
 
Screening test 
 
Population-oriented screening programs 
Non - population oriented 
screening programs 
 
Total 
Status Wome
n 
х 1000 
Status Wome
n 
х1000 
Wom
en 
х1000 
Austria Cytology   National 1 859 1 859 
Belgium   Cytology Regional, in progress 1 313 Regional 985 2 289 
Bulgaria    No program    1 490 
Croatia Cytology National, in progress 882   882 
Cyprus  No Program    195 
Czech 
Republic 
Cytology National. In progress 2 225   2 225 
Denmark Cytology National, implemented 1105   1 105 
Estonia Cytology National, implemented 271   271 
Finland Cytology National, implemented 1 042   1 042 
France Cytology Regional, in progress 1 788 Regional 11 279 13 
067 
Germany Cytology National, in the planning stage 16 974 National 16 974 16 
974 
Greece Cytology   National 2348 2 348 
Hungary Cytology National, in progress 2 091   2 091 
Ireland Cytology National, in progress 986   986 
Italy Cytology National, in progress 13 187   13 
187 
Latvia Cytology National, implemented 423   423 
Lithuania Cytology National, in progress 612   612 
Luxemburg Cytology   National 125 125 
Malta Cytology National, pilot program 18   85 
Netherland Cytology National, implemented 3 425   3 425 
Poland Cytology National, implemented 8 330   8 330 
Portugal Cytology Regional, in progress 1 616   2 293 
Romania Cytology National, in progress 4 166   4 166 
R. Slovakia Cytology National, implemented 1 197   1 197 
Slovenia Cytology National, implemented 440   440 
Spain Cytology   National 10 494 10 
491 
Sweden Cytology National, implemented 1 842   1 842 
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* Adult target groups in national population-oriented screening programs refer to individuals 
aged 30-59 years. 
* Germany is in the process of planning a population-oriented program based on HPV - test and 
cytology. 
* Although Germany has implemented a non-population-oriented screening program, in this 
table only the data on the population-oriented program are taken in consideration. 
* Malta in the implementation of the pilot program for organized population-oriented screening 
targets a small age group (25 - 35 years). 
Conclusion 
Cervical cancer is ranked as the ninth most common cancer among women in Europe and the 
fourth most common on a global scale. In Europe, there is currently a population of 325.3 
million women aged 15 and over at high risk. Among EU member states, the incidence of 
cervical cancer is generally lower compared to other European countries. However, the 
differences within the EU between old and new member states are also significant. On average, 
the incidence of cervical cancer in the European Union member states is 13.6/100 000. The 
incidence in the old EU14 member states (before May 2004) is 9.9/100 000 while the incidence 
in the new EU13 member states (after May 2004) is 19.7/100 000. According to the IARC 2012, 
the incidence of cervical cancer in the member states of the European Union is 13.6/100 000. 
The mortality rate for 2012 is 4.6. The number of deaths is 131,000. 
With the discovery of HPV vaccines, cervical cancer is considered an absolutely preventable 
disease. To date, three types of HPV vaccines are currently licensed. Cervarix, Gardasil and 
Gardasil 9. Vaccines are part of the mandatory immunization calendar of 21 European Union 
member states. 
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